Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesonide + formoterol
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
Budesonide + formoterol is a fixed-dose combination inhaled medication used for the maintenance treatment of asthma in patients aged 6 years and older, as well as for the maintenance treatment of airflow obstruction and reduction of exacerbations in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle to improve airflow. The combination provides both anti-inflammatory effects from budesonide and bronchodilation from formoterol, leading to improved symptom control in asthma and COPD[1][2][5][8].
- Brand names
- SymbicortSymbicort TurbuhalerSymbicort AerosphereBreyna
- Other names
- budesonide and formoterol fumarate dihydratebudesonide/formoterol
02
Targets
GR (Glucocorticoid receptor)ADRB3 (β3)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on budesonide + formoterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesonide + formoterol.